Neutrophils: the forgotten cell in JIA disease pathogenesis
James N Jarvis*1, Kaiyu Jiang1, Howard R Petty2 and Michael Centola3

Address: 1Department of Pediatrics, University of Oklahoma College of Medicine, Oklahoma City, OK 73014, USA, 2Department of Ophthalmology, University of Michigan School of Medicine, Kellogg Eye Institute, Ann Arbor, MI 48105, USA and 3Arthritis & Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA

Email: James N Jarvis* - james.jarvis@ouhsc.edu; Kaiyu Jiang - kaiyu.jiang@ouhsc.edu; Howard R Petty - hpetty@umich.edu; Michael Centola - michael.centola@omrf.ouhsc.edu
* Corresponding author

Abstract
Juvenile idiopathic arthritis (JIA) has long been assumed to be an autoimmune disease, triggered by aberrant recognition of "self" antigens by T-cells. However, systems biology approaches to this family of diseases have suggested complex interactions between innate and adaptive immunity that underlie JIA. In particular, new data suggest an important role for neutrophils in JIA pathogenesis. In this short review, we will discuss the new data that support a role for neutrophils in JIA, discuss regulatory functions that link neutrophils to adaptive immune responses, and discuss future areas of investigation. Above all else, we invite the reader to re-consider the use of the term "autoimmunity" as applied to the family of illnesses we collectively call JIA.

Note on nomenclature
The nomenclature used to categorize children with chronic arthritis has undergone considerable change over the years covered by this review. The most widely accepted classification scheme replaces the terms juvenile rheumatoid arthritis and juvenile chronic arthritis with the term juvenile idiopathic arthritis. However, it is important for the reader to note that the terms are not synonymous and classification schemes do not completely overlap. This leaves the reviewer with the vexing task of how to refer to earlier studies that used different classification schemes. For the sake of simplicity, clarity, and accuracy, we have elected to use whatever terms were used by the authors of the relevant studies in describing those studies, while adhering to the internationally-accepted classification scheme when speaking generically of chronic arthritis in children.

Background
With the possible exception of the systemic-onset form [1], juvenile idiopathic arthritis (JIA) has long been assumed to be an "autoimmune" disease. The autoimmune theory of pathogenesis has tenaciously held its position of unchallenged dogma in pediatric rheumatology, despite serious limits in its ability to explain all the known immunopathological phenomena and the paucity of evidence for either a T- or B-cell driven response (see below). At the same time, no competing theories for pathogenesis have emerged, so the autoimmune theory holds its ground by default. In this review, we will discuss emerging evidence that demonstrates the importance of neutrophils in regulating and informing the adaptive immune response, suggesting, therefore, that innate immunity may play a larger role in JIA pathogenesis than has been previously thought. We will then summarize new data from our laboratories that supports the hypothesis that neutrophil activation in JIA is a primary pathogenic event, and that involvement of the adaptive immune system is downstream of that primary event.

This paper is not intended as a comprehensive review of specific neutrophil function. Other authors have already
taken on that daunting task [e.g.,[2-5]]. We will summarize relevant neutrophil biology in context, however, in appropriate places in this text.

**Limits of the T cell centered hypothesis**

The presence of T cells within the inflamed synovium, the frequency of antinuclear antibodies, and the association of specific subtypes with specific HLA alleles [6] have all been powerful arguments that the illnesses collectively referred to as JIA represent an "autoimmune" disease whose pathogenesis is rooted in the dysregulation of mechanisms through which T cells distinguish "self" from "non-self" [7]. However, over the past 20 years, little additional evidence has accumulated to support T-cell centered theories of pathogenesis. Furthermore, our expanding knowledge has demonstrated equally plausible explanations for some of the phenomena on which the autoimmune hypothesis of JIA pathogenesis was built. For example, T cells can be found in joints of adults with gout [8,9] clearly demonstrating that the presence of T cells within a joint does not require autoimmune activation. Moreover, an increasing body of evidence demonstrates how T cells can be recruited to and activated in the synovial space [10-12] without engagement of the T cell-receptor-HLA complex, a process believed to be crucial in JIA pathogenesis. The pathological meaning of autoantibodies, and ANA in particular, in childhood arthritis becomes less significant as we have established that the presence of such autoantibodies is a common feature in childhood [13,14] and not necessarily a sign of dysregulated immunity. An additional Achilles heel of the autoimmune theory of JIA pathogenesis is the fact that HLA associations seen in one ethnic group are not found in others, suggesting that HLA is an associative, not mechanistic, linkage to JIA[15]. Finally, and perhaps most importantly, T cell-centered theories of JIA pathogenesis have not provided the foundation for a single new treatment for this disease. Current successful therapies are either non-specific (e.g., methotrexate) or target proteins that are critical elements of the innate immune response (e.g., TNFα). Thus, there is an urgent need to rethink the old paradigm and search more imaginatively for future targets of therapy.

**Neutrophils: seneschals of the adaptive immune response**

Immunologists have long overlooked the neutrophil. Lacking the elegant specificity of T and B cells and their intricate "dance" with antigen processing cells and multiple co-receptors, the neutrophil, with its, prepackaged arsenal of inflammatory ordnance, short life span, and all-too-well-recognized capacity to injure host tissue [16], appeared to be the "loose cannon" of the immune system. A more sophisticated model of neutrophil action has evolved as we have come to understand better the complex interplay between the innate and adaptive immune systems.

Until recently, it was common to think separately about innate and adaptive immunity. We typically think of innate immunity as occurring early in an immune response, being non-specific in nature, and completed at the time specific, adaptive immune mechanisms come into play. Although this view has the virtues of simplicity and clarity (and thus provides a useful heuristic framework), the truth is that innate and adaptive immunity display numerous points of intersection and co-regulation [17,18].

Neutrophils provide one of the critical points of intersection between innate and adaptive immunity. Indeed, we are now learning that neutrophils, like complement, play a critical role in instructing and shaping almost every aspect of the adaptive immune response.

Current states of knowledge suggest that an inflammatory response must begin with the immune system's sensing two classes of signals: tissue injury and the presence of a foreign genome [19]. The presence of only one is inadequate to begin the process. Surgery, for example, injures tissues, but excites a relatively modest inflammatory response because of its being performed steriley; commensurate bacterial flora expose us daily to foreign genetic material, but elicit little inflammatory response in the absence of tissue injury [20]. Neutrophils play a critical role in sensing these binary signals, and, of most importance to our understanding of JIA pathogenesis, can serve as a central point of orchestration of subsequent adaptive immune responses. Upon sensing the binary signals that trigger the inflammatory process, neutrophils begin a program that determines whether there will be a brisk, modest, or blunted immunologic response (see Figure 1). Release of neutrophil myeloperoxidase [21] and anti-bacterial cationic proteins [22] up-regulates HLA class II molecules and induces chemotaxis in monocytes. Similar effects are induced on dendritic cells, mediated, in part, by neutrophil release of TNFα[23,24]. However, neutrophils' influence on adaptive immunity extends beyond the early phases of antigen-presenting cell activation and immune response induction. Neutrophils also release the TNF-related ligand, B lymphocyte stimulator (BLyS), thus regulating the expansion and maturation of B cells [25]. In a similar vein, neutrophil-derived IFNγ regulates the activation and expansion of T cells [26].

Thus, rather than being "downstream" of the putative pathological events in JIA, neutrophils are arguably at the very center. Furthermore, data from patients with known autoinflammatory syndromes clearly demonstrate that disrupted innate immunity can lead to clearly defined aber-
studies appear to conflict (37). The applicability of these chemotaxis (36) (although, again, data from different conflicting data that suggest otherwise (35)) and normal with the activated state (33,34) (although there are con-
tinuing neutrophil function in adult rheumatoid disease, of active disease. There is a more extensive literature exam-
istered theories of JIA pathogenesis? Isn't it time to look
rations in adaptive immunity [27-29]. How, then, can the field of pediatric rheumatology avoid a detailed study of the neutrophil as we confront the limitations of T cell-cen-
tered theories of JIA pathogenesis? Isn't it time to look upstream? These are rhetorical questions; it should be obvious from the data that has emerged in the past 7 years that we no longer can avoid a systematic examination of neutrophil function in JIA, especially now that we have improved tools and methodologies for doing so. In all fairness, given the paucity of information that emerged from early studies of neutrophils in JIA, it is easy to see why this area was relatively neglected for so long.

**Neutrophils in JRA/JIA: early studies**

Early interest in neutrophils derived from the fact that they are the most abundant cell within JRA synovial fluid [30]. Several early studies examined neutrophil chemo-
taxis, with some showing no differences when JRA neut-
rophils were compared with controls [31] and others showing increased motility of JRA neutrophils [32] although the increases were observed only during periods of active disease. There is a more extensive literature exam-
ing neutrophil function in adult rheumatoid disease, although they, too, provide conflicting data. Studies of circ-
ulating neutrophils from adults with rheumatoid arthri-
tis have generally reported absence of markers associated with the activated state [33,34] (although there are con-
flicting data that suggest otherwise [35]) and normal chemotaxis [36] (although, again, data from different studies appear to conflict [37]). The applicability of these findings to childhood-onset disease is uncertain when thinking in traditional terms of neutrophil function. More recent studies suggest that these studies were inconclusive because neutrophils' regulatory potential may be more rel-
ent than their effector functions in JIA pathology.

With so much conflicting data, it is easy to see why pedi-
atrian rheumatologists quickly dropped the neutrophil to explore other potentially more productive areas of immu-
ology. By the 1990s, the neutrophil had all but disapp-
peared from the pediatric rheumatology literature, with the exception of a single study from Poland [38], a study whose significance was unappreciated at the time. All of this changed seven years ago, as an understanding of neut-
rophils regulatory potential began to unfold.

**Evidence for chronic neutrophil activation in JIA/JRA**

In 2000, Frosch and colleagues from the University of Munster in Germany reported their investigations with myeloid-related proteins (MRP-8 and -14) in juvenile rheumatoid arthritis [39]. These proteins are made by both monocytes and neutrophils and are released during leukocyte interactions with endothelium [40]. These authors reported a striking correlation between MRP-8 and -14 levels and disease activity in a cohort of children with pauciarticular JRA. While these authors assumed that monocytes were the cell of origin for the proteins, subsequent work from this same group (examining the related protein, S100 A12) attributed the abundance of S100 pro-
teins in JRA sera to neutrophil activation [41]. Indeed, neutrophil (or monocyte)-derived S100 proteins are beginning to emerge as a potentially useful clinical biomarker to monitor response to therapy in children with JIA. At the risk of generating some healthy contro-
versy, it is worth pointing out that no reliable T- or B-cell based biomarker for response to therapy in JIA has emerged in the past 20 years.

Before the publication of the Frosch and Foell papers, we had posited that JIA immune pathogenesis very likely involves complex interactions between innate and adap-
tive immunity [42] and ongoing work from our group has aimed at elucidating those interactions [43]. We have therefore undertaken a "systems biology" [44,45] approach to polyarticular JIA in an effort to obtain the "global view" of these interactions [46]. In a preliminary study, designed largely to develop methodologies [43], we examined gene expression profiles of whole blood buffy coats in a small group (n = 9) of children with active JRA. In that study, we were quite surprised to see over-expression of genes either expressed by neutrophils (e.g., ferritin heavy and light chains, N-formyl peptide receptor) or reg-
ulating neutrophil function (e.g., IL-8) in children with JRA. These data were consistent with the data emerging
from the Frosch and Foell studies; neutrophils likely play an important role in JRA/JIA pathogenesis.

We next performed gene expression profiling on neutrophils of 25 children with JRA, 15 of whom were studied during periods of active and inactive disease as defined by Wallace and colleagues [47]. In that study, we demonstrated aberrant patterns of gene expression in neutrophils of children with polyarticular JIA, even when their disease was inactive [48]. Indeed, hierarchical clustering analysis, a method for asking, "Which group is most like the other group?" scattered patients with active and inactive disease indistinguishably, as shown in Figure 2. Even more interesting were in silico models of the differentially-expressed genes (Figure 3), which showed clusters of IFNγ and IL-8-related genes, the significance of which will be explained shortly. Subsequent work from our laboratory has shown that these expression abnormalities persist even when children fit consensus criteria for remission (unpublished data). This contrasts with what we have reported in peripheral blood mononuclear cells of children with JIA, where gene expression profiles normalize after therapy [49]. The obvious question is, "What is this defect, and what can we do about it?"

**Neutrophils as oscillators**

The key as to where the defect in JIA/JRA neutrophils might lie emerged from the in silico modeling of the gene expression data. As noted above, computer modeling of the functional relationships between the different genes suggested linked networks of IL-8 and IFNγ-regulated genes. The significance of this finding may lie in the underlying dynamic properties of cell chemistry.

Oscillations are found throughout nature, from bacteria to man [50]. Oscillations show three characteristics: frequency, amplitude, and phase; examples of these are the heart rate, stroke volume, and relative timing of the opening of the heart valves. In addition to this macroscopic example, oscillations in calcium signaling, mitosis, and hormone action have been studied.

Neutrophil oscillations were first reported in the late 1980s (e.g., Jager et al [51]). Since that time, a broad variety of neutrophil oscillations has been reported and their relationship to human disease documented [52]. These oscillations are not peripheral events in cell behavior, but, rather, are a central element of neutrophil activation, and therefore potentially critical to our understanding human inflammatory diseases.

Renewed interest in the phenomenon of neutrophil oscillations began with observations demonstrating physical proximity between β2 integrins and other cell-surface receptors, which allowed the integrins to serve as signal transducers for glycosphatidylinositol (GPI)-linked proteins. Furthermore, when receptor proximity on living cells (e.g., between the complement receptor CR4 and urokinase plasminogen activator receptor [uPAR]) was measured with resonance energy transfer microscopy, it was found to oscillate in time [53]. The fact that all of the CR4 and uPAR molecules either come into proximity or move away from each other simultaneously implies biological coherence in receptor action; the receptors are not behaving as individual signaling units but as a collective. Moreover, the period of CR4-uPAR oscillation was similar to that reported previously by other research groups for other neutrophil oscillators. Furthermore, the shape of the oscillatory waves could be modulated by suboptimal doses of kinase and phosphatase inhibitors, indicating that the dynamic uPAR-CR4 interactions are coupled with oscillatory signal transduction machinery. This suggests that the structural and functional oscillations of neutrophils are tied to the same fundamental chemical oscillator. The heterogeneity of the oscillators, such as receptor properties, membrane potential, shape, actin, etc would simply reflect the experimental readouts employed.

Subsequent work in the Petty laboratory has directly linked cell metabolism, oscillatory phenomena, and cell

![Figure 2](image-url)
signaling [54]. This has been achieved by measuring fluctuations in NAD(P)H levels, which respond parallel to, but 180° out of phase, with ATP. Furthermore, because NAD(P)H is fluorescent, fluctuations can be measured without perturbing the cells (although NADH and NADPH cannot be distinguished spectroscopically). Subsequent work in the Petty laboratory using NAD(P)H autofluorescence has shown that (1) metabolic oscillations drive receptor signaling and receptor oscillations; (2) variations in NAD(P)H amplitude and frequency are carried “downstream” to other functional, oscillatory phenomena such as superoxide and nitric oxide production; (3) the period of NAD(P)H oscillations is tightly linked to the key event in neutrophil activation, glucose influx.

A wide variety of biological materials are known to influence intracellular calcium signaling. Similarly, this group has discovered numerous materials that influence the amplitude or frequency of calcium and/or metabolic oscillations. These include fMLP, immune complexes, IFNγ, TNFα, and others [55,56]. It is important to note that specific agents regulate specific aspects of the oscillatory phenomena. Specifically, wave amplitude and wave frequency are regulated independently, and the mechanisms that regulate each are stringently insulated from one-another. Some of the relevant mediators can be summarized as follows:

1. IFNγ and PMA trigger amplitude modulation of the oscillations.
2. TNFα, IL-8, fMLP, and immune complexes cause calcium and metabolic oscillations to double in frequency.

Figure 3
In silico modeling derived from Pathway Assist software analysis of differential gene expression in JRA neutrophils compared with healthy control subjects. Note clusters of IFNγ- (lower right) and IL-8- (lower left) regulated genes. From Jarvis et al, *Arthritis Res Therapy* 2006. The authors retain the copyright for this material.
3. Other biological response modifiers, including IL-2 and IL-6, double oscillation frequency, but only during concurrent amplitude modulation, e.g., with IFNγ.

With this as a background, we get back to interpreting the gene expression profile in JRA neutrophils. The patterns of IL-8 and IFNγ-regulated gene expression suggested that it would be fruitful to examine other fundamental cellular processes regulated by those mediators, specifically NAD(P)H oscillations. The findings suggested a fundamental breakdown of the processes that insulate frequency and amplitude regulation in JRA neutrophils, as shown in Figure 4. That is, agents that normally evoke only increases in NAD(P)H frequency (LPS, immune complexes), induced both frequency and amplitude enhancement in a subset of JRA neutrophils. This defect was observed in patients with both active and inactive disease. Thus, we assume that this defect may be primary, although the possibility that it is caused or driven by more fundamental aberrations in adaptive immunity cannot be excluded.

Redefining the pathogenic paradigm and exploring the future

It is time to ask whether the T cell deserves the place it has held for so long in the center of JIA pathogenic paradigms. While there is insufficient data to replace the central place of the T cell with the neutrophil (although Figure 1 accounts for the known data as well as us than the T cell centered paradigm), it is time to give neutrophils their due place. New data from multiple laboratories, using techniques as diverse as genomics, in silico modeling, and single-cell microscopy, all suggest that we have overlooked the critical role neutrophils may play in JIA pathogenesis. Furthermore, these data account for observed phenomena not explainable by T cell-centered hypotheses (e.g., the applicability of S100 proteins as biomarkers of response). Furthermore, they account for the known involvement of adaptive immunity far better than T cell-centered hypotheses account for the known involvement of the innate immune system, although there is reason to believe the interaction is bi-directional [57]. Indeed, the efficacy of anti-inflammatory therapies, such as anakinra [58], MRA [59], thalidomide[60] (a powerful suppressor of neutrophil function), as well as T cell inhibitory therapy (abatacept, cyclosporine) suggests that distorted cross-talk innate between adaptive immunity is a critical element in JIA pathogenesis. We would simply argue that this does not necessarily imply that the dysfunctional relationship starts with T cells.

There is still much to do. It is very likely that we will need rigorous applications of systems biology approaches and ongoing cooperation between laboratories invested in both innate and adaptive immunity to unravel the complexities that are only now coming into focus. It is clear that we know little of the molecular basis of disease pathology and nothing of the etiology of any of the forms of JIA. Maybe a short moratorium on the word, “autoimmune,” as applied to this family of diseases, is in order, since use of the word suggests that we already know where the relevant immunopathogenic events may reside. Above all, we need to be bold and creative in our thinking, ready to cut loose from comfortable paradigms, humble in admission of what we still don’t know, and persistent in our determination to get better answers for hundreds of thousands of children and young adults with arthritis.

Acknowledgements

JNj - Supported by a grant from the Arthritis Foundation Innovative Research Grant Program and R21-AR-48378 from the National Institutes of Health

HRP – Supported by R01-AI51789 from the National institutes of Health

MC – Supported by grants P20RR016478, 5U19AI062629, P20RR15577, P20RR17703 from the National Institutes of Health and grant HR04-110 from the Oklahoma Center for the Advancement of Science and Technology

The authors would like to thank Dr. Julie McGhee, St. Louis Children Hospital, for proofreading and suggestions with this manuscript.

References

1. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J: Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005, 201:1479-1486.
2. Sheppard FR, Kelher MR, Moore EE, McLaughlin NJ, Banerjee A, Silliman CC. Structural organization of the neutrophil NADPH oxidase: phosphorylation and transduction during priming and activation. J Leukocyte Biol 2005; 78:1025-1042.

3. Segal AW: How neutrophils kill microbes. Ann Rev Immunol 2005, 23:197-223.

4. Van Haastert PJ, Devreotes PN: Chemotaxis: signalling the way forward. Nature Rev Mol Cell Biol 2004, 5:626-634.

5. Niggli V: Signaling to migration in neutrophils: importance of localized pathways. Int J Biochem Cell Biol 2003, 35:1619-1638.

6. Ferre O, Dobloug JH, Heyerahl H, Thorsby E: HLA antigens in juvenile arthritis. Genetic basis for the different subtypes. Arthritis Rheum 1993, 26:1321-1332.

7. Morimoto C, Romain PL, Fox DA, Anderson P, DiMaggio M, Levine H, Schlossman SF: Abnormalities in CD4+ T-lymphocyte subsets in inflammatory rheumatic diseases. Am J Med 1988, 84:17-23.

8. Xiao S, Xu C-S, Jarvis JN: C1q-bearing immune complexes induce IL-8 secretion in human umbilical vein endothelial cells (HUVEC) through protein tyrosine kinase- and mitogen-activated protein kinase-dependent mechanisms. Evidence for the role of the 126 kD phagocytic C1q receptor mediates immune complex activation of HUVEC. Clin Exp Immunol 2001, 125:360-367.

9. Jiang K, Chen Y, Xu C-S, Jarvis JN: T-cell activation by soluble C1q-bearing immune complexes: implications for the pathogenesis of rheumatoid arthritis. Clin Exp Immunol 2003, 131:61-67.

10. Jiang K, Chen Y, Jarvis JN: Cord blood and adult T cells show different responses to C1q-bearing immune complexes. Cell Immunol 2006, 229:62-67.

11. Cabral DA, Pesty RE, Jung M, Balles P. Persistent antinuclear antibodies in children without identifiable rheumatic or autoimmune disease. Pediatr 1992, 89:441-444.

12. Mollenhauer BM, Parish IA, Janzen L, Huisman J: Usefulness of antinuclear antibody testing to screen for rheumatic diseases. Arch Dis Child 1997, 77:299-304.

13. Li W, Wang M, Irigoyen P, Gregersen PK: Inferring causal relationships among intermediate phenotypes and biomarkers: a case study of rheumatoid arthritis. Bioinformatics 2006, 22:1503-1507.

14. Brown KA, Brain SD, Pearson JD, Edgeworth JD, Lewis SM, Treacher DF: Neutrophils in development of multiple organ failure in sepsis. Lancet 2006, 368:157-169.

15. Fearon DT, Locksley RM: The instructive role of innate immune responses in the induction of adaptive immunity. Science 1996, 272:50-53.

16. Carroll MC: The role of complement and complement receptors in the regulation of immunity. Ann Rev Immunol 1998, 16:545-568.

17. Nathan C: Inflammation: points of control. Nature 2002, 420:846-852.

18. Nathan C: Neutrophils and immunity: challenges and opportunities. Nature Rev Immunol 2006, 6:173-182.

19. Lefkowitz DL, Gelderman MP, Fuhrmann SR, Graham S, Starnes JD III, Lefkowitz SS, Bollen A, Mogulovsky N. Neutrophil myeloperoxidase-macrophage interactions perpetuate chronic inflammation associated with experimental arthritis. Clin Immunol 1999, 91:145-155.

20. Pereira HA, Shafer WM, Pohl J, Martin LE, Spitznagel JK: CAP37, a human neutrophil-derived chemoattractant factor with monocytotoxic specificity. J Clin Invest 1990, 85:904-915.

21. Bonnemaa S, Bliss SK, Curiel Tj, Denkers EY: Cross-talk in the innate immune system: neutrophils instruct recruitment and activation of dendritic cells during microbial infection. J Immunol 2003, 171:6052-6058.

22. Bonnemaa S, Denkers EY: Microbial antigen triggers rapid mobilization of TNF-alpha to the surface of mouse neutrophils transforming them into inducers of high-level dendritic cell TNF-alpha production. J Immunol 2005, 174:4845-4851.

23. Scapini P, Carletto A, Nardiello B, Calzetti F, Rosciche V, Mergio F, Tamassia N, Pierorgan S, Basidi R, Sterbati A, Sozzani S, Barbara L, Cassata MA: Proinflammatory mediators elicited upon interaction of the intracellular B-Lymphocyte stimulator protein (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases. Blood 2005, 105:830-837.

24. Ethum F, Gerard B, Benna JE, Bouchon A, Gougerot-Pocidalo MA, Jacob L, Chollet-Martinson S. Human neutrophils produce interferon gamma upon stimulation by interleukin-12. Lab Invest 2004, 84:1363-1371.

25. Ayapra E, Ozen S, Okur H, Kutuk T, Basbas N, Bakkaragolu A: Th1 polarization in familial Mediterranean fever. J Rheumatol 2011-2013.

26. Musabak U, Sengul A, Oktenli C, Pay S, Yesilova Z, Kenar L, Sanisoglu SY, Inal A, Tuzun A, Erdil A, Bagci S. Does immune activation continue during an attack-free period in familial Mediterranean fever? Clin Exp Immunol 2004, 138:526-533.

27. Petiti RE, Cassidy JT: Juvenile Rheumatoid Arthritis. In Textbook of Pediatric Rheumatology Edited by: Cassidy JT, Petey RE. Philadelphia: WB Saunders Co; 2001.p 262.

28. Trum PG, Prieur AM, Griscelli C: Neutrophil chemotaxis in juvenile chronic arthritis. Ann Rheum Dis 1980, 39:481-484.

29. Frosch M, Kullmers W, Kupetz H: Proinflammatory activity of blood polymorphonuclear leukocytes during juvenile rheumatoid arthritis, demonstrated with a new whole blood membrane filter assay. Inflammation 1994, 18:427-441.

30. Lopez S, Halwachs-Mecarelli L, Ravaud P, Bessoux G, Douagos M, Porte T: Neutrophil expression of tumour necrosis factor receptors (TNF-R) and of activation markers (CD11b, CD43, CD63) in rheumatoid arthritis. Clin Exp Immunol 1995, 101:25-32.

31. Benna J, Hayem G, Dang PM, Fay M, Chollet-Martinson S, Elcbim C, Meyer O, Gougerot-Pocidalo MA: NADPH oxidase priming and p47phox phosphorylation in neutrophils from synovial fluid of patients with rheumatoid arthritis and spondylarthropathy. Inflammation 1997, 20:273-278.

32. Torsgna D, Capraro D, Arvidsson NG, Hallgren R, Halskann L: Enhanced expression of integrins and CD66b on peripheral blood neutrophils and eosinophils patients with rheumatoid arthritis, and the effect of glucocorticoids. Scand J Immunol 1999, 50:433-439.

33. Bostan M, Constant M, Nicolau A, Hirt M, Galateau C, Matei I, Brasoveanu L, Iordachescu D: Study of chemotactic activity developed by neutrophils from rheumatoid arthritis patients. Rom Arch Microbiol Immunol 2002, 61:243-258.

34. Myer J, Hermann E, Egger G: Abnormal directed migration of blood polymorphonuclear leukocytes in rheumatoid arthritis. Potential role in increased susceptibility to bacterial infections. Mediators Inflamm 1998, 7:19-23.

35. Sikora A, Brozik H, Sikora JP, Golebiowski M: Chemiluminescence of peripheral blood leukocytes and activity of an inflammatory process in juvenile chronic arthritis (JCA). Acta Universitatis Carolinae - Medicina 1994, 40:75-79.

36. Frosch M, Streu A, Vogt T, Wulfraat NM, Kuw S, Sunderkotter C, Harms E, Sorg C, Roth J: Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000, 43:628-637.

37. Foell D, Roth J: Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 2005, 50:3762-3771.

38. Foell D, Winkowski H, Hammerschmidt I, Wulfraat N, Schmelting H, Frosch M, Hornef G, Kuw S, Sorg C, Roth J: Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum 50:1286-1295.

39. Jarvis JN: Mechanisms of pathogenesis and inflammation in the pediatric rheumatic diseases. Curr Opinion Rheumatol 1998, 10:459-467.

40. Jarvis JN, Dozonrovi M, Jiang K, Frank MB, Szodoray P, Alex P, Centola M: Novel approaches to gene expression analysis of active polyarticular juvenile rheumatoid arthritis. Arthritis Res...
44. Ottino JM: Engineering complex systems. Nature 2004, 427:399.
45. Kirschner MW: The meaning of systems biology. Cell 2005, 121:503-504.
46. Jarvis JN: Gene expression arrays in juvenile rheumatoid arthritis: will the blind men finally see the elephant? Curr Prob Pae Diatrics Adolesc Health Care 2006, 36:91-96.
47. Wallace CA, Ruperto N, Giannini E: Childhood Arthritis and Rheumatology Research Alliance. Pediatric Rheumatology International Trials Organization. Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. Journal Rheumatol 2004, 31:2290-2294.
48. Jarvis JN, Petty HR, Tang Y, Frank MB, Tessier PA, Dozmorov I, Jiang K, Kindzelski A, Chen Y, Cadwell, Turner M, McGhee JL, Centola M: Evidence for chronic, peripheral activation of neutrophils in polyarticular juvenile rheumatoid arthritis. Arthritis Res Therapy 2006, 8:R154.
49. Dozmorov I, Knowlton N, Tang Y, Shields A, Pathipvanich P, Jarvis JN, Centola M: Hypervariable genes – experimental error or hidden dynamics. Nucleic Acids Res 2004, 32:e147.
50. Petty HR: Neutrophil oscillations: temporal and spatiotemporal aspects of cell behavior. Immunol Res 2001, 23:85-94.
51. Jager U, Gruler HB, Bultman B: Morphological changes and membrane potential of human granulocytes under influence of chemotactic peptide and/or echovirus, type 8. Klin Wochenschr 1988, 66:434-436.
52. Adachi Y, Kindzelskii AL, Cookingham G, Shayua S, Moore EC, Todd RF III, Petty HR: Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol 1998, 111:154-158.
53. Kindzelskii AL, Eszes MM, Todd RF III, Petty HR: Proximity oscillations of complement receptor type 4 and urokinase receptors on migrating neutrophils are linked with signal transduction/metabolic oscillations. Biophys J 1997, 73:1777-1784.
54. Kindzelskii AL, Petty HR: Apparent role of traveling metabolic waves in oxidant release by living neutrophils. Proc Natl Acad Sci (USA) 2002, 99:9207-9212.
55. Petty HR: Neutrophil oscillations: temporal and spatiotemporal aspects of cell behavior. Immunologic Res 2000, 23:85-94.
56. Stark J, Chan C, George AJ: Oscillations in the immune system. Immunol Res 2007, 216:213-231.
57. Ley K, Smith E, Stark MA: IL-17A-producing neutrophil regulatory Tn lymphocytes. Immunol Res 2006, 34:229-242.
58. Verbsky JW, White AJ: Effective use of the recombinant interleukin-1 receptor agonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004, 31:2071-2075.
59. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, Woe P, Nishimoto N, Yoshizaki K, Kishimoto T: Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005, 52:818-825.
60. Lehman TJ, Schechter SJ, Sundel RP, Oliveira SK, Huttonlocher A, Ossel KB: Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. J Pediatr 2004, 145:856-857.